Evidence map›Paper›PMID 35896860›Full record

SynthesisStem cell reviews and reports2022

Paracrine Factors Released by Stem Cells of Mesenchymal Origin and their Effects in Cardiovascular Disease: A Systematic Review of Pre-clinical Studies.

Nishani S Mabotuwana, Lavinia Rech, Joyce Lim, Sean A Hardy, Lucy A Murtha, Peter P Rainer, Andrew J Boyle

Open access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Stem cell reviews and reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Nishani S MabotuwanaCollege of Health, Medicine and Wellbeing, The University of Newcastle, Newcastle, NSW, Australia.
Lavinia RechDepartment of Internal Medicine, Division of Cardiology, Medical University of Graz, Graz, Austria.
Joyce LimCollege of Health, Medicine and Wellbeing, The University of Newcastle, Newcastle, NSW, Australia.
Sean A HardyCollege of Health, Medicine and Wellbeing, The University of Newcastle, Newcastle, NSW, Australia.
Lucy A MurthaCollege of Health, Medicine and Wellbeing, The University of Newcastle, Newcastle, NSW, Australia.
Peter P RainerDepartment of Internal Medicine, Division of Cardiology, Medical University of Graz, Graz, Austria.
Andrew J BoyleCollege of Health, Medicine and Wellbeing, The University of Newcastle, Newcastle, NSW, Australia. Andrew.boyle@newcastle.edu.au.
Hunter Medical Research Institute · AUMedical University of Graz · ATUniversity of Newcastle Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cell (MSC) therapy has gained significant traction in the context of cardiovascular repair, and have been proposed to exert their regenerative effects via the secretion of paracrine factors. In this systematic review, we examined the literature and consolidated available evidence for the "paracrine hypothesis". Two Ovid SP databases were searched using a strategy encompassing paracrine mediated MSC therapy in the context of ischemic heart disease. This yielded 86 articles which met the selection criteria for inclusion in this study. We found that the MSCs utilized in these articles were primarily derived from bone marrow, cardiac tissue, and adipose tissue. We identified 234 individual protective factors across these studies, including VEGF, HGF, and FGF2; which are proposed to exert their effects in a paracrine manner. The data collated in this systematic review identifies secreted paracrine factors that could decrease apoptosis, and increase angiogenesis, cell proliferation, and cell viability. These included studies have also demonstrated that the administration of MSCs and indirectly, their secreted factors can reduce infarct size, and improve left ventricular ejection fraction, contractility, compliance, and vessel density. Furthering our understanding of the way these factors mediate repair could lead to the identification of therapeutic targets for cardiac regeneration.

Indexed as

Cardiovascular DiseasesMesenchymal Stem Cell TransplantationMyocardial InfarctionHumansParacrine CommunicationStroke VolumeVentricular Function, LeftCardiac regenerationCardiac repairMesenchymal stem cellMyocardial ischemiaParacrineSecreted

Identifiers

PMID35896860
PMCPMC9622561
OpenAlexW4288074441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.